CIPLANSECipla Limited· PharmaceuticalsHighPositive
Announced Wed, 13 May · 12:43 IST

Cipla Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2026, recommended Final Dividend of Rs. 13 per equity share.

Corporate Actions View source PDF

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.9%1-day move
₹1293.70
prior close
₹1323.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.3-0.4+2.0+10.9+10.4+10.2+8.9+8.2+7.7+8.4+6.8+10.3
Up moveDown movePending
AI summary

Cipla's Board has recommended a final dividend of Rs. 13 per equity share (face value Rs. 2) for FY ended March 2026, subject to shareholder approval at the ensuing AGM. The record date for dividend entitlement is June 5, 2026. Consolidated net profit for FY2026 declined to Rs. 3,862 Crores from Rs. 5,269 Crores in FY2025, impacted by a Rs. 276 Crores exceptional charge from new labour code implementation (gratuity and leave liabilities) and a Rs. 42 Crores impairment in associate investments. Consolidated revenue grew marginally to Rs. 27,712 Crores from Rs. 27,145 Crores. Standalone net profit stood at Rs. 3,515 Crores with EPS of Rs. 43.52. The company also completed acquisition of Inzpera Healthsciences for Rs. 111 Crores and has a scheme of amalgamation pending for the subsidiary.

Likely market impact

The dividend recommendation signals management confidence in sustaining shareholder returns despite a near 27% decline in net profit. The Rs. 13 dividend likely represents a steady or improved payout compared to prior year. However, the profit decline and exceptional items may warrant caution on the stock near-term.